Osteomyelitis Clinical Trial
Official title:
Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)
The Infectious Diseases Society of America (IDSA) 2012 guidelines for the diagnosis and
treatment of diabetic foot infections state that for the treatment of diabetic foot
osteomyelitis "No data support the superiority of any specific antibiotic agent or treatment
strategy, route, or duration of therapy." Traditionally, osteomyelitis has been treated with
a long course of intravenous antibiotics, generally six weeks. Oral antibiotics with high
bioavailability and adequate bone penetration have been shown in published studies to be
effective for the treatment of osteomyelitis.
The investigators propose to conduct a prospective, single-center, randomized, open trial at
Loyola University Medical Center (LUMC) comparing the efficacy of oral antibiotic therapy to
intravenous (IV) antibiotic therapy for the treatment of diabetic foot osteomyelitis. The
investigators hypothesize that oral antibiotic therapy is equivalent to IV antibiotic
therapy. Bone/tissue cultures are obtained for all patients for clinical purposes and are
sent to pathology for histologic examination and to the clinical microbiology laboratory for
culture and susceptibility. Patients will receive six weeks of IV or oral antibiotic therapy
depending upon their randomization group. Primary outcomes at six months clinical follow-up
will include: (i) no evidence of bone infection and (ii) resolution of ulcer.
Currently, available literature is not adequate to determine the best agent, route, or
duration of antibiotic therapy for the treatment of chronic osteomyelitis. The standard of
therapy has been to treat patients with a parenteral antibiotic for four to six weeks. In a
recent literature review by Spellberg et al. it was concluded that oral and parenteral
antibiotic therapy have similar cure rates for the treatment of chronic osteomyelitis. Oral
antibiotic therapy is associated with a lower risk to the patient due to avoiding the need of
a central IV line. Additionally, oral therapy costs less than a course of IV antibiotics.
Oral antibiotics with high bioavailability and good bone penetration include,
fluoroquinolones, linezolid, trimethoprim/sulfamethoxazole (2 tabs bid), clindamycin and
metronidazole. These antibiotics have been shown in recent studies to obtain levels in the
bone that exceed the minimum inhibitory concentration (MIC) levels of the targeted organisms.
According to the IDSA 2012 guidelines for the treatment of diabetic foot infections, the
diagnosis of osteomyelitis can be made via plain radiographs or MRI imaging (more sensitive).
A bone scan can be considered if an MRI cannot be done. The preferred method of diagnosis is
by bone culture and histology. The guidelines also recommend surgical debridement to healthy
tissue for diabetic foot infections followed by antibiotic therapy.
The Purpose of this study is to compare the efficacy of oral antibiotic therapy with
intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis following
surgical debridement. They hypothesis is that oral antibiotic therapy is equivalent to
intravenous antibiotic therapy for the treatment of diabetic foot osteomyelitis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Completed |
NCT03846804 -
Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
|
N/A | |
Active, not recruiting |
NCT04945434 -
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis
|
N/A | |
Recruiting |
NCT06084754 -
Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis
|
N/A | |
Recruiting |
NCT05177107 -
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT04554108 -
Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses.
|
N/A | |
Recruiting |
NCT02128256 -
CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis
|
Phase 4 | |
Terminated |
NCT01612962 -
Diagnostic Tests to Help Determine Osteomyelitis
|
N/A | |
Terminated |
NCT03091439 -
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
|
Phase 2 | |
Recruiting |
NCT04936958 -
RETR(Osteomyelitis)
|
||
Completed |
NCT03802552 -
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
|
Phase 1 | |
Completed |
NCT03559530 -
Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
|
||
Completed |
NCT00324922 -
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
|
Phase 3 | |
Completed |
NCT02084147 -
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
|
N/A | |
Terminated |
NCT02099240 -
Patients Response to Early Switch To Oral:Osteomyelitis Study
|
Early Phase 1 | |
Withdrawn |
NCT02344511 -
Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis
|
Phase 3 | |
Completed |
NCT00402064 -
The Influence of Bisphosphonates in the Oral Cavity in Children
|
N/A | |
Completed |
NCT02685033 -
Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
|
Phase 2 | |
Completed |
NCT02335905 -
Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
|
Phase 1/Phase 2 |